BioSenic SA

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: BE0974280126
EUR
0.00
0.00 (0.00%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About BioSenic SA stock-summary
stock-summary
BioSenic SA
Pharmaceuticals & Biotechnology
Bone Therapeutics SA is a Belgium-based company developing cell therapy products. The Company develops cell therapy products for the treatment and regeneration of bone tissue and bone reconstruction applications, osteonecrosis, ununited fractures, and maxillo-facial reconstruction. It is engaged in research, enable adult stem cell isolation, expansion, and osteogenic differentiation.The Company’s therapeutic area focus is bone diseases, with extensions to joint, mainly osteoarthritis and disc degeneration.
Company Coordinates stock-summary
Company Details
Rue Auguste Piccard 37 , GOSSELIES None : 6041
stock-summary
Tel: 32 71 12100032 071 121000
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Jean Stephenne
Chairman of the Board
Dr. Miguel Forte
Chief Executive Officer, Executive Director
Mr. Jean-Luc Vandebroek
Chief Financial Officer, Executive Director
Mrs. Claudia D'Augusta
Independent Director
Mr. Damian Marron
Independent Director
Dr. Gloria Matthews
Independent Director
Dr. Jean-Paul Prieels
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
(Quarterly Results - )
Net Profit:
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

EUR 2 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.09

stock-summary
Return on Equity

26.76%

stock-summary
Price to Book

-0.06